# US 2025/0367218 A1 · Methods of treating metabolic disorders and combination products for use in the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367218 A1
- Document ID: US20250367218A1
- Status: Published application
- Kind: A1
- Application number: 19/208,467
- Filed: 2025-05-14
- Published: 2025-12-04
- Earliest claimed: 2024-05-14
- Assignees: Carlos Batthyány; Institut Pasteur de Montevideo; Universidad de la República; Minozar S.A.
- Applicants: Institut Pasteur De Montevideo; Universidad De La RepúBlica; Minozar S.A.
- Inventors: Carlos José Escande Castro; Gloria Virginia Lopez; Carlos Ignacio Batthyány Dighiero; Maria Pia Garat; Karina Beatriz Cal Castillo; Santiago Ruiz Perera; Leonardo Santos; Maria Valentina Perez Torrado
- Web page: https://patentgrep.com/patent/US20250367218A1

## CPC

- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/60: Salicylic acid; Derivatives thereof
- A61K 38/26: Glucagons
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to methods of treating a metabolic disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a nitro-vinyl benzene compound and administering to the subject a therapeutically effective amount of a GLP-1 agonist or analog. The present invention is also directed to kits and/or pharmaceutical compositions suitable for practicing the claimed methods.

## Claims

### Claim at position 1

-31. (canceled)

### Claim 32

A method of treating a disease or disorder in a subject in need thereof, comprising:
administering to the subject a therapeutically effective amount of compound (I)
or a pharmaceutically acceptable salt thereof; and
administering to the subject a therapeutically effective amount of a GLP-1 agonist or analog,
wherein the disease or disorder is selected from obesity, type 2 diabetes, MASH (Metabolic dysfunction-associated steatohepatitis), non-alcoholic fatty liver disease, metabolic dysfunction-associated fatty liver disease, non-alcoholic steatohepatitis, and/or fibrosing non-alcoholic steatohepatitis or a combination thereof in a mammal.

### Claim 33 (depends on 32)

The method of claim 32, wherein the GLP-1 agonist or analog is selected from: albiglutide (Tanzeum), aleniglipron (GSBR-1290), AMG133 (maridebart cafraglutide, MariTide), amycretin, AP025, AP026, ARI-2255, ARI-2651, bamadutide (SAR425899), beinaglutide, BGM0504 (BGM-0504, BGM 0504), BI-456906 (survodutide), bimagrumab, cagrilintide, CagriSema (cagrilintide+semaglutide), CAM-2056, cinchonine, cotadutide, CT-388 (RG6640), CT-868 (RG6641), CT-996 (RG6652), CVX-096, DA-15864, DA-3091 (microsphere formulation of exenatide), danuglipron (PF-06882961), dapiglutide (ZP7570), DD-01, DR10624, dulaglutide (Trulicity), ECC5004, ecnoglutide (XW003 (Injectable), XW004 (Oral)), efinopegdutide (HM12525A, MK-6024), efocipegtrutide (HM15211), efpeglenatide (LAPSExd4 analog, HM11260C), exenatide (Byetta, Bydureon/Bydurcon BCise), Exendin-4, GL0034 (utreglutide), GLP-1, GLP-1 eligen, Glucagon, GMA106, GRMD-0901 (ORMD-0901), GSBR-1290 (aleniglipron), GSK-2374697, HEC88473, HM15275, HRS-9531, HS-20094, HZ010, HZ012, ID110521156, Injectable HDV GLP1, Insulin glargine and lixisenatide (soliqua 100/33, LixiLan), JY09, langlenatide, LAPSGlucagon Combo (HM14320), 1Liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin (US), Lyxumia (EU)), lotiglipron (PF-07081532), loxenatide, LY-2189265, LY-3305677, MAR-701, MAR709, mazdutide (IBI362, OXM3), MDR-001, MET-097i, MK-8521, MKC-253, MOD-6030, MOD-6031, noiiglutide (SHR20004, HS 20004), NN9423, NN-9709, NN-9924 (Oral semaglutide), NN-9926, NN-9277, NNC0090-2746, NNC0487-0111, NNC0519-0130, OPK88003, Oral HDV GLP1, orforglipron (LY3502970), ORMD-0901 (GRMD-0901), OWL-833, oxyntomodulin, PB-1023, PB-718, pegapamodutide, pemvidutide (ALT-801), petrelintide, PF-07081532 (lotiglipron), PF-07976016, PYY 1875 (NNC0165-1875), retatrutide (LY3437943, GGG Tri-agonist), rExendin-4, RGT-075, SAR425899 (bamadutide), SAR441255, SCO-094, semaglutide (Ozempic, Rybelsus, Wegovy), Septerna GLP-1R/GIPR/GCGR, SHR-1816, survodutide (BI-456906), taspoglutide, TB001, TG103, tirzepatide (Mounjaro, Zepbound), TT-401, TTP-054, TTP-273, UBT251, Viador-GLP-1, VK2735, vurolenatide, XW014, ZP-2929, ZP-3022, ZP-DI-70, ZP5750, ZYD-1, ZYOG-1, polymer-bound analogs thereof, pegylated analogs thereof, pharmaceutically acceptable salts thereof, and combinations thereof.

### Claim 34 (depends on 32)

The method of claim 32, wherein the GLP-1 agonist or analog is selected from semaglutide, liraglutide, and pharmaceutically acceptable salts thereof.

### Claim 35 (depends on 32)

The method of claim 32, wherein the therapeutically effective amount of compound (I) or pharmaceutically acceptable salt thereof is about 0.1 mg to about 400 mg, and the therapeutically effective amount of the GLP-1 agonist or analog is about 0.25 mg to about 2.4 mg.

### Claim 36 (depends on 32)

The method of claim 32, wherein the therapeutically effective amount of compound (I) or pharmaceutically acceptable salt thereof is about 0.1 mg to about 400 mg, and the therapeutically effective amount of the GLP-1 agonist or analog is about 3 mg to about 14 mg.

### Claim 37 (depends on 32)

The method of claim 32, wherein the therapeutically effective amount of compound (I) or pharmaceutically acceptable salt thereof is about 0.1 mg to about 400 mg, the therapeutically effective amount of the GLP-1 agonist or analog is about 0.6 mg to about 1.8 mg.

### Claim 38 (depends on 32)

The method of any of claim 32, wherein the subject in need thereof undergoes a reduction in body weight within 30 days of beginning treatment.

### Claim 39 (depends on 32)

The method of any of claim 32, wherein the disease or disorder is obesity.

### Claim 40 (depends on 32)

The method of claim 32, wherein the subject in need thereof is a subject being administered a therapeutically effective amount of GLP-1 agonist or analog, the method comprising:
determining the subject's current dose of GLP-1 agonist or analog;
administering to the subject a therapeutically effective amount of compound (I)
or a pharmaceutically acceptable salt thereof; and
administering to the subject a lower dose of the GLP-1 agonist or analog.

### Claim 41 (depends on 32)

The method of claim 32, wherein at least one side effect or adverse effect associated with the GLP-1 agonist or analog is reduced in frequency, severity, or a combination thereof.

### Claim 42 (depends on 32)

The method of claim 32, wherein the lower dose of the GLP-1 agonist or analog is at least 30% lower than the current dose, preferably at least 40% lower than the current dose, and most preferably at least 50% lower than the current dose.

### Claim 43 (depends on 32)

The method of claim 32, wherein the GLP-1 agonist or analog is selected from tirzepatide, orforglipron, and pharmaceutically acceptable salts thereof.

### Claim 44

A method of reducing body weight, body fat, or a combination thereof in a subject in need thereof, the method comprising:
administering to the subject a therapeutically effective amount of a GLP-1 agonist or analog; and
administering to the subject a therapeutically effective amount of compound (I)
or a pharmaceutically acceptable salt thereof.

### Claim 45 (depends on 44)

The method of claim 44, further comprising maintaining body weight, body fat, or a combination thereof in a subject in need thereof, the method further comprising:
administering to the subject a therapeutically effective amount of a GLP-1 agonist or analog; and
administering to the subject a therapeutically effective amount of compound (I) or a pharmaceutically acceptable salt thereof.

### Claim 46 (depends on 44)

The method of claim 44, wherein the GLP-1 agonist or analog is selected from:
albiglutide (Tanzeum), aleniglipron (GSBR-1290), AMG133 (maridebart cafraglutide, MariTide), amycretin, AP025, AP026, ARI-2255, ARI-2651, bamadutide (SAR425899), beinaglutide, BGM0504 (BGM-0504, BGM 0504), BI-456906 (survodutide), bimagrumab, cagrilintide, CagriSema (cagrilintide+semaglutide), CAM-2056, cinchonine, cotadutide, CT-388 (RG6640), CT-868 (RG6641), CT-996 (RG6652), CVX-096, DA-15864, DA-3091 (microsphere formulation of exenatide), danuglipron (PF-06882961), dapiglutide (ZP7570), DD-01, DR10624, dulaglutide (Trulicity), ECC5004, ecnoglutide (XW003 (Injectable), XW004 (Oral)), efinopegdutide (HM12525A, MK-6024), efocipegtrutide (HM15211), efpeglenatide (LAPS Exd4 analog, HM11260C), exenatide (Byetta, Bydureon/Bydureon BCise), Exendin-4, GL0034 (utreglutide), GLP-1, GLP-1 eligen, Glucagon, GMA106, GRMD-0901 (ORMD-0901), GSBR-1290 (aleniglipron), GSK-2374697, HEC88473, HM15275, HRS-9531, HS-20094, HZ010, HZ012, ID110521156, Injectable HDV GLP1, Insulin glargine and lixisenatide (soliqua 100/33, LixiLan), JY09, langlenatide, LAPSGlucagon Combo (HM14320), 1Liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin (US), Lyxumia (EU)), lotiglipron (PF-07081532), loxenatide, LY-2189265, LY-3305677, MAR-701, MAR709, mazdutide (IBI362, OXM3), MDR-001, MET-097i, MK-8521, MKC-253, MOD-6030, MOD-6031, noiiglutide (SHR20004, HS 20004), NN9423, NN-9709, NN-9924 (Oral semaglutide), NN-9926, NN-9277, NNC0090-2746, NNC0487-0111, NNC0519-0130, OPK88003, Oral I-DV GLP1, orforglipron (LY3502970), ORMD-0901 (GRMD-0901), OWL-833, oxyntomodulin, PB-1023, PB-718, pegapamodutide, pemvidutide (ALT-801), petrelintide, PF-07081532 (lotiglipron), PF-07976016, PYY 1875 (NNC0165-1875), retatrutide (LY3437943, GGG Tri-agonist), rExendin-4, RGT-075, SAR425899 (bamadutide), SAR441255, SCO-094, semaglutide (Ozempic, Rybelsus, Wegovy), Septerna GLP-1R/GIPR/GCGR, SHR-1816, survodutide (BI-456906), taspoglutide, TB001, TG103, tirzepatide (Mounjaro, Zepbound), TT-401, TTP-054, TTP-273, UBT251, Viador-GLP-1, V1K2735, vurolenatide, XW014, ZP-2929, ZP-3022, ZP-DI-70, ZP5750, ZYD-1, ZYOG-1, polymer-bound analogs thereof, pegylated analogs thereof, pharmaceutically acceptable salts thereof, and combinations thereof.

### Claim 47 (depends on 44)

The method of claim 44 wherein the GLP-1 agonist or analog is selected from semaglutide, liraglutide, and pharmaceutically acceptable salts thereof.

### Claim 48 (depends on 44)

The method of claim 44, wherein the subject in need thereof experiences a reduction in body weight within the first 30 days of administering the therapeutically effective amount of compound (I) or a pharmaceutically acceptable salt thereof.

### Claim 49 (depends on 44)

The method of claim 44, wherein the GLP-1 agonist or analog is selected from tirzepatide, orforglipron, and pharmaceutically acceptable salts thereof.

### Claim 50

A method of preventing weight gain in a subject currently taking a GLP-1 agonist or analog comprising:
administering to the subject a therapeutically effective amount of compound (I)
or a pharmaceutically acceptable salt thereof to the subject.

### Claim 51 (depends on 50)

The method of claim 50, further comprising discontinuing the GLP-1 agonist or analog.

### Claim 52 (depends on 45)

The method of claim 45, wherein the maintaining body weight, body fat, or a combination thereof in a subject in need thereof is maintaining body weight, body fat, or a combination thereof upon a reduction in dose of the GLP-1 agonist or analog, the method further comprising:
administering to the subject a therapeutically effective amount of a GLP-1 agonist or analog at a reduced dose; and
administering to the subject a therapeutically effective amount of compound (I) or a pharmaceutically acceptable salt thereof.

### Claim 53 (depends on 50)

The method of claim 50 wherein the preventing of weight gain in a subject currently taking a GLP-1 agonist or analog occurs upon a reduction in dose of the GLP-1 agonist or analog.
